ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
128.027,59
-0,38%
S&P 500
5.308,15
1,17%
US Dollar vs BRL
5,1351
0,00%
Bitcoin
66.133,86
-0,19%
Brent Oil
82,97
0,38%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. IDEAYA Biosciences Inc (IDYA)

  7. IDEAYA Biosciences Inc (IDYA) Notícias

IDYA

IDEAYA Biosciences (IDYA)

IDEAYA Biosciences Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:IDYA
DataHoraFonteTítuloCódigoCompanhia
07/05/202407:04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IDYAIDEAYA Biosciences Inc
07/05/202407:00PR Newswire (US)IDEAYA Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:IDYAIDEAYA Biosciences Inc
01/05/202407:00PR Newswire (US)IDEAYA Biosciences to Participate in Upcoming May 2024 Investor Relations EventNASDAQ:IDYAIDEAYA Biosciences Inc
26/04/202407:00PR Newswire (US)IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:IDYAIDEAYA Biosciences Inc
24/04/202411:05PR Newswire (US)IDEAYA Biosciences Announces ASCO 2024 Oral Presentation for Darovasertib in Neoadjuvant Uveal Melanoma Phase 2 Investigator Sponsored StudyNASDAQ:IDYAIDEAYA Biosciences Inc
22/04/202407:00PR Newswire (US)IDEAYA Biosciences Announces Selection of Move-Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP-Deletion Squamous Non-Small Cell Lung CancerNASDAQ:IDYAIDEAYA Biosciences Inc
01/04/202407:00PR Newswire (US)IDEAYA Biosciences to Participate in Upcoming April 2024 Investor Relations EventNASDAQ:IDYAIDEAYA Biosciences Inc
12/03/202407:00PR Newswire (US)IDEAYA Announces Clinical Collaboration to Evaluate IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial CancerNASDAQ:IDYAIDEAYA Biosciences Inc
04/03/202419:27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IDYAIDEAYA Biosciences Inc
04/03/202408:00PR Newswire (US)IDEAYA Biosciences to Participate in Upcoming March 2024 Investor Relations EventsNASDAQ:IDYAIDEAYA Biosciences Inc
20/02/202418:31Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:IDYAIDEAYA Biosciences Inc
20/02/202408:00PR Newswire (US)IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business UpdateNASDAQ:IDYAIDEAYA Biosciences Inc
14/02/202408:44Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:IDYAIDEAYA Biosciences Inc
09/02/202419:56Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:IDYAIDEAYA Biosciences Inc
01/02/202408:00PR Newswire (US)IDEAYA Biosciences to Participate in Upcoming February 2024 Investor Relations EventsNASDAQ:IDYAIDEAYA Biosciences Inc
19/01/202419:15Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:IDYAIDEAYA Biosciences Inc
07/01/202411:00PR Newswire (US)IDEAYA Biosciences Announces Participation at the 42nd Annual J.P. Morgan Healthcare Conference and 2024 Corporate GuidanceNASDAQ:IDYAIDEAYA Biosciences Inc
05/12/202308:00PR Newswire (US)IDEAYA Biosciences to Participate in Upcoming December 2023 Investor Relations EventNASDAQ:IDYAIDEAYA Biosciences Inc
04/12/202308:00PR Newswire (US)IDEAYA Announces Clinical Study Collaboration with Gilead Sciences to Evaluate Trodelvy® and IDE397 Combination in MTAP-Deletion Bladder CancerNASDAQ:IDYAIDEAYA Biosciences Inc
03/12/202311:00PR Newswire (US)IDEAYA Announces Agenda for Investor R&D Day Webcast on December 4, 2023NASDAQ:IDYAIDEAYA Biosciences Inc
07/11/202318:01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IDYAIDEAYA Biosciences Inc
07/11/202308:00PR Newswire (US)IDEAYA Biosciences, Inc. Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:IDYAIDEAYA Biosciences Inc
01/11/202307:00PR Newswire (US)IDEAYA Biosciences Announces Plans for Investor R&D Day and Participation in Jefferies London Healthcare ConferenceNASDAQ:IDYAIDEAYA Biosciences Inc
27/10/202317:02PR Newswire (US)IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional SharesNASDAQ:IDYAIDEAYA Biosciences Inc
24/10/202323:15PR Newswire (US)IDEAYA Announces Pricing of Public OfferingNASDAQ:IDYAIDEAYA Biosciences Inc
24/10/202317:07PR Newswire (US)IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsNASDAQ:IDYAIDEAYA Biosciences Inc
23/10/202307:00PR Newswire (US)IDEAYA Announces Top-Line Phase 2 Results at ESMO 2023 of Darovasertib and Crizotinib Combo in MUM, and Clinical Efficacy Updates for Neoadjuvant UM, GNAQ/11 Cutaneous Melanoma, and Synthetic Lethality PipelineNASDAQ:IDYAIDEAYA Biosciences Inc
17/10/202307:00PR Newswire (US)IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2023 for Phase 2 Clinical Data Update for Darovasertib and Crizotinib Combination in Metastatic Uveal MelanomaNASDAQ:IDYAIDEAYA Biosciences Inc
16/10/202307:00PR Newswire (US)IDEAYA Biosciences Announces Phase 2 Expansion of Darovasertib and Crizotinib Combination in GNAQ/11 Metastatic Cutaneous MelanomaNASDAQ:IDYAIDEAYA Biosciences Inc
09/10/202307:00PR Newswire (US)IDEAYA Biosciences Announces Development Candidate Nomination of a Werner Helicase Inhibitor in Collaboration with GSK and Investor R&D DayNASDAQ:IDYAIDEAYA Biosciences Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:IDYA

Seu Histórico Recente

BOV
GOLL4
GOL PN
BOV
IBOV
Índice Bovespa
BOV
LUPA3
LUPATECH ON
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados